Q3 Asset Management Summit Therapeutics Inc. Transaction History
Q3 Asset Management
- $283 Million
- Q2 2025
A detailed history of Q3 Asset Management transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Q3 Asset Management holds 19,567 shares of SMMT stock, worth $408,950. This represents 0.15% of its overall portfolio holdings.
Number of Shares
19,567
Previous 16,473
18.78%
Holding current value
$408,950
Previous $317,000
31.23%
% of portfolio
0.15%
Previous 0.22%
Shares
3 transactions
Others Institutions Holding SMMT
# of Institutions
260Shares Held
90.4MCall Options Held
4.71MPut Options Held
3.17M-
Baker Bros. Advisors LP New York, NY33.7MShares$705 Million7.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.67MShares$181 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$165 Million0.0% of portfolio
-
State Street Corp Boston, MA4.02MShares$84 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.91MShares$81.6 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.21B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...